Cargando…

JAK inhibitors: A new dawn for oral therapies in inflammatory bowel diseases

Inflammatory bowel disease (IBD) is a chronic immune-mediated condition of the gastrointestinal tract that requires chronic treatment and strict surveillance. Development of new monoclonal antibodies targeting one or a few single cytokines, including anti-tumor necrosis factor agents, anti-IL 12/23...

Descripción completa

Detalles Bibliográficos
Autores principales:	Herrera-deGuise, Claudia, Serra-Ruiz, Xavier, Lastiri, Ernesto, Borruel, Natalia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Medicine
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10017532/ https://www.ncbi.nlm.nih.gov/pubmed/36936239 http://dx.doi.org/10.3389/fmed.2023.1089099

Ejemplares similares

Leishmania infantum asymptomatic infection in inflammatory bowel disease patients under anti-TNF therapy
por: Guillén, M. Carmen, et al.
Publicado: (2020)

User's guide to JAK inhibitors in inflammatory bowel disease
por: Spiewak, Ted A., et al.
Publicado: (2022)

Fungal and Bacterial Loads: Noninvasive Inflammatory Bowel Disease Biomarkers for the Clinical Setting
por: Sarrabayrouse, G., et al.
Publicado: (2021)

Hi-JAKi-ng Synovial Fibroblasts in Inflammatory Arthritis With JAK Inhibitors
por: Burja, Blaž, et al.
Publicado: (2020)

Dawn of Precision Medicine in Psoriatic Arthritis
por: Miyagawa, Ippei, et al.
Publicado: (2022)

Animal Models of Inflammatory Bowel Disease at the Dawn of the New Genetics Era
por: Sollid, Ludvig M, et al.
Publicado: (2008)

Therapeutic drug monitoring in inflammatory bowel disease: The dawn of reactive monitoring
por: Albader, Farah, et al.
Publicado: (2021)

Gastroenterology in the Metaverse: The dawn of a new era?
por: Zhang, Chi, et al.
Publicado: (2022)

Efficacy and Safety of Biological Therapies and JAK Inhibitors in Older Patients with Inflammatory Bowel Disease
por: Fries, Walter, et al.
Publicado: (2023)

Impact of the COVID-19 pandemic on the activity of advanced-practice nurses on a reference unit for inflammatory bowel disease
por: Navarro-Correal, Ester, et al.
Publicado: (2021)

Impact of the COVID-19 pandemic on the activity of advanced-practice nurses on a reference unit for inflammatory bowel disease
por: Navarro-Correal, Ester, et al.
Publicado: (2021)

The dawn of hedgehog inhibitors: Vismodegib
por: Sandhiya, Selvarajan, et al.
Publicado: (2013)

Co Treatment With Biologic Agents and Immunotherapy in the Setting of irAEs of Difficult Management
por: Robles-Alonso, Virginia, et al.
Publicado: (2022)

JAK1 inhibition and inflammatory bowel disease
por: Harris, Clare, et al.
Publicado: (2021)

Dawn of Monitoring Regulatory T Cells in (Pre-)clinical Studies: Their Relevance Is Slowly Recognised
por: de Wolf, A. Charlotte M. T., et al.
Publicado: (2020)

Tofacitinib and newer JAK inhibitors in inflammatory bowel disease—where we are and where we are going
por: Liu, Eleanor, et al.
Publicado: (2022)

Ileocolonic-Targeted JAK Inhibitor: A Safer and More Effective Treatment for Inflammatory Bowel Disease
por: Yadav, Vipul, et al.
Publicado: (2022)

JAK Inhibitors and Modulation of B Cell Immune Responses in Rheumatoid Arthritis
por: Moura, Rita A., et al.
Publicado: (2021)

Effectiveness and Safety of JAK Inhibitors in Autoinflammatory Diseases: A Systematic Review
por: Boyadzhieva, Zhivana, et al.
Publicado: (2022)

Sucrosomial Iron Supplementation for the Treatment of Iron Deficiency Anemia in Inflammatory Bowel Disease Patients Refractory to Oral Iron Treatment
por: Bastida, Guillermo, et al.
Publicado: (2021)

Multi-utility of therapeutic drug monitoring in inflammatory bowel diseases
por: Martins, Camilla de Almeida, et al.
Publicado: (2022)

Oral Nirmatrelvir/Ritonavir Therapy for COVID-19: The Dawn in the Dark?
por: Hung, Yuan-Pin, et al.
Publicado: (2022)

JAK1 inhibitor abrocitinib for the treatment of steroid-induced rosacea: case series
por: Xu, Bingyang, et al.
Publicado: (2023)

Prognostication in inflammatory bowel disease
por: Spencer, Elizabeth A., et al.
Publicado: (2022)

JAK inhibitors for the treatment of inflammatory bowel disease: results of an international survey of perceptions, attitudes, and clinical practice
por: Honap, Sailish, et al.
Publicado: (2023)

Biomarkers Predictive of Response to Thiopurine Therapy in Inflammatory Bowel Disease
por: Cornish, Jack S., et al.
Publicado: (2020)

Therapeutic siRNAs Targeting the JAK/STAT Signalling Pathway in Inflammatory Bowel Diseases
por: Clément, Flora, et al.
Publicado: (2021)

Intestinal Epithelium in Inflammatory Bowel Disease
por: Coskun, Mehmet
Publicado: (2014)

Serum Biomarkers for Inflammatory Bowel Disease
por: Chen, Peng, et al.
Publicado: (2020)

Are Probiotics or Prebiotics Useful in Pediatric Irritable Bowel Syndrome or Inflammatory Bowel Disease?
por: Guandalini, Stefano
Publicado: (2014)

JAK1/2 Inhibitor Baricitinib Improves Skin Fibrosis and Digital Ulcers in Systemic Sclerosis
por: Hou, Zhanying, et al.
Publicado: (2022)

New Strategies for Treatment of Inflammatory Bowel Disease
por: Nielsen, Ole Haagen
Publicado: (2014)

Predicting Response to Vedolizumab in Inflammatory Bowel Disease
por: Meserve, Joseph, et al.
Publicado: (2020)

Co-pathogens in Periodontitis and Inflammatory Bowel Disease
por: Cai, Zhengwen, et al.
Publicado: (2021)

Editorial: Game Changers in Inflammatory Bowel Diseases
por: Bálint, Anita, et al.
Publicado: (2021)

The temple of dawn
por: Mishima, Yukio, 1925-1970
Publicado: (1970)

The dawn of magic
por: Pauwels, Louis
Publicado: (1964)

The Dawn of Litholapaxy
Publicado: (1900)

The Dawn of Character
Publicado: (1911)

Trisomy 8 Associated Clonal Cytopenia Featured With Acquired Auto-Inflammation and Its Response to JAK Inhibitors
por: Fu, Yakai, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_qh6mfdb3dojndrkgql021rjqmi